Name | Number of supported studies | Average coverage | |
---|---|---|---|
brain | 19 studies | 29% ± 12% | |
lung | 18 studies | 44% ± 19% | |
peripheral blood | 18 studies | 40% ± 13% | |
intestine | 9 studies | 24% ± 6% | |
kidney | 7 studies | 35% ± 11% | |
liver | 6 studies | 41% ± 18% | |
heart | 6 studies | 60% ± 18% | |
breast | 5 studies | 27% ± 9% | |
bone marrow | 4 studies | 38% ± 15% | |
uterus | 4 studies | 36% ± 9% | |
eye | 4 studies | 38% ± 22% | |
lymph node | 4 studies | 38% ± 8% | |
adipose | 4 studies | 52% ± 14% | |
prostate | 3 studies | 29% ± 10% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
esophagus | 100% | 11273.45 | 1445 / 1445 | 100% | 30.46 | 183 / 183 |
stomach | 100% | 8502.31 | 359 / 359 | 99% | 20.08 | 283 / 286 |
thymus | 100% | 14134.80 | 653 / 653 | 98% | 31.00 | 595 / 605 |
pancreas | 100% | 8377.04 | 327 / 328 | 98% | 28.84 | 175 / 178 |
lung | 100% | 22430.19 | 578 / 578 | 98% | 23.63 | 1132 / 1155 |
breast | 100% | 10399.81 | 458 / 459 | 98% | 21.33 | 1095 / 1118 |
intestine | 100% | 9670.70 | 965 / 966 | 98% | 18.13 | 514 / 527 |
skin | 100% | 9014.57 | 1809 / 1809 | 97% | 17.36 | 459 / 472 |
prostate | 100% | 8719.57 | 245 / 245 | 96% | 15.41 | 483 / 502 |
kidney | 99% | 4768.54 | 88 / 89 | 96% | 19.19 | 867 / 901 |
uterus | 100% | 25172.66 | 170 / 170 | 93% | 15.44 | 429 / 459 |
bladder | 100% | 13161.71 | 21 / 21 | 93% | 12.51 | 470 / 504 |
ovary | 100% | 10425.78 | 180 / 180 | 87% | 9.56 | 374 / 430 |
adrenal gland | 99% | 5944.17 | 255 / 258 | 87% | 12.97 | 200 / 230 |
liver | 98% | 4293.04 | 221 / 226 | 77% | 8.24 | 313 / 406 |
brain | 45% | 1300.64 | 1198 / 2642 | 98% | 15.54 | 691 / 705 |
adipose | 100% | 11699.08 | 1204 / 1204 | 0% | 0 | 0 / 0 |
lymph node | 0% | 0 | 0 / 0 | 100% | 20.70 | 29 / 29 |
muscle | 100% | 11360.18 | 803 / 803 | 0% | 0 | 0 / 0 |
spleen | 100% | 13362.49 | 241 / 241 | 0% | 0 | 0 / 0 |
ureter | 0% | 0 | 0 / 0 | 100% | 5.36 | 1 / 1 |
blood vessel | 100% | 10269.95 | 1334 / 1335 | 0% | 0 | 0 / 0 |
heart | 99% | 16635.93 | 849 / 861 | 0% | 0 | 0 / 0 |
peripheral blood | 97% | 10665.61 | 901 / 929 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 96% | 15.71 | 77 / 80 |
tonsil | 0% | 0 | 0 / 0 | 96% | 17.22 | 43 / 45 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
GO_0000165 | Biological process | MAPK cascade |
GO_0007507 | Biological process | heart development |
GO_0055007 | Biological process | cardiac muscle cell differentiation |
GO_0051056 | Biological process | regulation of small GTPase mediated signal transduction |
GO_0007186 | Biological process | G protein-coupled receptor signaling pathway |
GO_0086023 | Biological process | adenylate cyclase-activating adrenergic receptor signaling pathway involved in heart process |
GO_0043123 | Biological process | positive regulation of canonical NF-kappaB signal transduction |
GO_0035023 | Biological process | regulation of Rho protein signal transduction |
GO_0060297 | Biological process | regulation of sarcomere organization |
GO_0060348 | Biological process | bone development |
GO_0035025 | Biological process | positive regulation of Rho protein signal transduction |
GO_0071875 | Biological process | adrenergic receptor signaling pathway |
GO_0016020 | Cellular component | membrane |
GO_0030864 | Cellular component | cortical actin cytoskeleton |
GO_0015629 | Cellular component | actin cytoskeleton |
GO_0005829 | Cellular component | cytosol |
GO_0005938 | Cellular component | cell cortex |
GO_0005634 | Cellular component | nucleus |
GO_0005085 | Molecular function | guanyl-nucleotide exchange factor activity |
GO_0060090 | Molecular function | molecular adaptor activity |
GO_0005078 | Molecular function | MAP-kinase scaffold activity |
GO_0031267 | Molecular function | small GTPase binding |
GO_0046872 | Molecular function | metal ion binding |
GO_0051018 | Molecular function | protein kinase A binding |
GO_0005515 | Molecular function | protein binding |
Gene name | AKAP13 |
Protein name | A-kinase anchoring protein 13 AKAP13 protein A-kinase anchor protein 13 (AKAP-13) (AKAP-Lbc) (Breast cancer nuclear receptor-binding auxiliary protein) (Guanine nucleotide exchange factor Lbc) (Human thyroid-anchoring protein 31) (Lymphoid blast crisis oncogene) (LBC oncogene) (Non-oncogenic Rho GTPase-specific GTP exchange factor) (Protein kinase A-anchoring protein 13) (PRKA13) (p47) AKAP13 |
Synonyms | HT31 LBC BRX |
Description | FUNCTION: Scaffold protein that plays an important role in assembling signaling complexes downstream of several types of G protein-coupled receptors. Activates RHOA in response to signaling via G protein-coupled receptors via its function as Rho guanine nucleotide exchange factor . May also activate other Rho family members . Part of a kinase signaling complex that links ADRA1A and ADRA1B adrenergic receptor signaling to the activation of downstream p38 MAP kinases, such as MAPK11 and MAPK14 . Part of a signaling complex that links ADRA1B signaling to the activation of RHOA and IKBKB/IKKB, leading to increased NF-kappa-B transcriptional activity . Part of a RHOA-dependent signaling cascade that mediates responses to lysophosphatidic acid (LPA), a signaling molecule that activates G-protein coupled receptors and potentiates transcriptional activation of the glucocorticoid receptor NR3C1 . Part of a signaling cascade that stimulates MEF2C-dependent gene expression in response to lysophosphatidic acid (LPA) (By similarity). Part of a signaling pathway that activates MAPK11 and/or MAPK14 and leads to increased transcription activation of the estrogen receptors ESR1 and ESR2 . Part of a signaling cascade that links cAMP and EGFR signaling to BRAF signaling and to PKA-mediated phosphorylation of KSR1, leading to the activation of downstream MAP kinases, such as MAPK1 or MAPK3 . Functions as a scaffold protein that anchors cAMP-dependent protein kinase (PKA) and PRKD1. This promotes activation of PRKD1, leading to increased phosphorylation of HDAC5 and ultimately cardiomyocyte hypertrophy (By similarity). Has no guanine nucleotide exchange activity on CDC42, Ras or Rac . Required for normal embryonic heart development, and in particular for normal sarcomere formation in the developing cardiomyocytes (By similarity). Plays a role in cardiomyocyte growth and cardiac hypertrophy in response to activation of the beta-adrenergic receptor by phenylephrine or isoproterenol . Required for normal adaptive cardiac hypertrophy in response to pressure overload . Plays a role in osteogenesis (By similarity). . |
Accessions | ENST00000612418.1 A0A087WTD7 H0YMW2 ENST00000560579.5 H0YK18 ENST00000560256.1 ENST00000558811.2 A0A087WYS7 ENST00000559486.2 ENST00000560302.5 [Q12802-5] ENST00000394510.6 B7ZW05 A0A087X047 H0YK84 ENST00000559362.5 ENST00000394518.7 [Q12802-1] ENST00000560340.5 A0A087WY36 ENST00000557852.2 H0YLH1 ENST00000558166.2 ENST00000361243.6 [Q12802-2] A8MYJ1 A0A087WX73 H0YMI5 Q12802 A0A2X0SF55 ENST00000560676.5 |